109 related articles for article (PubMed ID: 16222010)
1. Preliminary observations on the efficacy of a recombinant multistage Plasmodium falciparum vaccine in Aotus nancymai monkeys.
Collins WE; Galland GG; Barnwell JW; Udhayakumar V; Sullivan JS; Nace D; Tongren JE; Williams T; Roberts J; Shi YP; Lal AA
Am J Trop Med Hyg; 2005 Oct; 73(4):686-93. PubMed ID: 16222010
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.
Kumar S; Yadava A; Keister DB; Tian JH; Ohl M; Perdue-Greenfield KA; Miller LH; Kaslow DC
Mol Med; 1995 Mar; 1(3):325-32. PubMed ID: 8529111
[TBL] [Abstract][Full Text] [Related]
3. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys.
Collins WE; Walduck A; Sullivan JS; Andrews K; Stowers A; Morris CL; Jennings V; Yang C; Kendall J; Lin Q; Martin LB; Diggs C; Saul A
Am J Trop Med Hyg; 2000 Apr; 62(4):466-79. PubMed ID: 11220762
[TBL] [Abstract][Full Text] [Related]
5. Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 alpha protects against severe disease during Plasmodium falciparum reinfection.
Makobongo MO; Keegan B; Long CA; Miller LH
J Infect Dis; 2006 Mar; 193(5):731-40. PubMed ID: 16453270
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.
Moreno CA; Rodriguez R; Oliveira GA; Ferreira V; Nussenzweig RS; Moya Castro ZR; Calvo-Calle JM; Nardin E
Vaccine; 1999 Aug; 18(1-2):89-99. PubMed ID: 10501239
[TBL] [Abstract][Full Text] [Related]
7. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.
Hisaeda H; Saul A; Reece JJ; Kennedy MC; Long CA; Miller LH; Stowers AW
J Infect Dis; 2002 Mar; 185(5):657-64. PubMed ID: 11865423
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and efficacy trials in Aotus nancymai monkeys with model compounds representing parts of a 75-kD merozoite surface antigen of Plasmodium falciparum.
Sharma P; Ruebush TK; Campbell GH; Richman SJ; Wilkins PP; Broderson JR; Ardeshir F; Gross M; Silverman C; Skinner JC
Am J Trop Med Hyg; 1992 Jun; 46(6):691-707. PubMed ID: 1621894
[TBL] [Abstract][Full Text] [Related]
9. Selection of different strains of Plasmodium falciparum for testing blood-stage vaccines in Aotus nancymai monkeys.
Collins WE; Galland GG; Sullivan JS; Morris CL
Am J Trop Med Hyg; 1994 Aug; 51(2):224-32. PubMed ID: 8074257
[TBL] [Abstract][Full Text] [Related]
10. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen.
Jones TR; Narum DL; Gozalo AS; Aguiar J; Fuhrmann SR; Liang H; Haynes JD; Moch JK; Lucas C; Luu T; Magill AJ; Hoffman SL; Sim BK
J Infect Dis; 2001 Jan; 183(2):303-312. PubMed ID: 11110648
[TBL] [Abstract][Full Text] [Related]
11. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.
Darko CA; Angov E; Collins WE; Bergmann-Leitner ES; Girouard AS; Hitt SL; McBride JS; Diggs CL; Holder AA; Long CA; Barnwell JW; Lyon JA
Infect Immun; 2005 Jan; 73(1):287-97. PubMed ID: 15618165
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
Stoute JA; Gombe J; Withers MR; Siangla J; McKinney D; Onyango M; Cummings JF; Milman J; Tucker K; Soisson L; Stewart VA; Lyon JA; Angov E; Leach A; Cohen J; Kester KE; Ockenhouse CF; Holland CA; Diggs CL; Wittes J; Heppner DG;
Vaccine; 2007 Jan; 25(1):176-84. PubMed ID: 16388879
[TBL] [Abstract][Full Text] [Related]
13. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.
Stowers AW; Cioce V; Shimp RL; Lawson M; Hui G; Muratova O; Kaslow DC; Robinson R; Long CA; Miller LH
Infect Immun; 2001 Mar; 69(3):1536-46. PubMed ID: 11179324
[TBL] [Abstract][Full Text] [Related]
15. Efficiency of human Plasmodium falciparum malaria vaccine candidates in Aotus lemurinus monkeys.
Herrera S; Herrera MA; Certa U; Corredor A; Guerrero R
Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():423-8. PubMed ID: 1343722
[TBL] [Abstract][Full Text] [Related]
16. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
[TBL] [Abstract][Full Text] [Related]
17. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
Ockenhouse CF; Angov E; Kester KE; Diggs C; Soisson L; Cummings JF; Stewart AV; Palmer DR; Mahajan B; Krzych U; Tornieporth N; Delchambre M; Vanhandenhove M; Ofori-Anyinam O; Cohen J; Lyon JA; Heppner DG;
Vaccine; 2006 Apr; 24(15):3009-17. PubMed ID: 16356603
[TBL] [Abstract][Full Text] [Related]
18. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.
Kumar S; Collins W; Egan A; Yadava A; Garraud O; Blackman MJ; Guevara Patino JA; Diggs C; Kaslow DC
Infect Immun; 2000 Apr; 68(4):2215-23. PubMed ID: 10722622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
